Par Pharmaceutical Holdings Inc. filed its Form S-1 Friday with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the number of shares in the offering or the pricing, but the offering is valued up to $100 million. The company has not yet chosen which market to list on, but it does plan on listing under the symbol PRX.

The underwriters for the offering are J.P. Morgan, Citigroup, Merrill Lynch, RBC Capital Markets, Deutsche Bank, Goldman Sachs, Morgan Stanley, Evercore ISI and TPG Capital.

In 2012, Par Pharma was acquired by TPG for $1.9 billion after activist firm Relational Investors called for the company to sell itself. Since that time, and under the watch of TPG, Par Pharma acquired JHP Group Holdings for $490 million in January 2014.

Par Pharma specializes in developing, licensing, manufacturing, marketing and distributing generic drugs. It has a generics portfolio of roughly 95 products across a very broad range. The company’s goal is to strengthen its position as a leading pharmaceutical company by developing and commercializing generic drugs with limited competition, significant barriers to entry and longer life cycles.

ALSO READ: 4 Top Pharmaceutical Stocks to Buy for Market Safety

As of the end of 2014, Par Pharma had more than 200 products in its pipeline, which included 115 Abbreviated New Drug Applications (ANDA) pending with the U.S. Food and Drug Administration (FDA). These represent $36.7 billion of combined annual sales for the corresponding branded products in 2014, including 32 potential first-to-file and six potential first-to-market opportunities.

In the filing, Par Pharma describes its segments:

Our company operates in two business segments, Par Pharmaceutical, which includes generic products marketed under Par Pharmaceutical and sterile products marketed under Par Sterile Products, LLC (“Par Sterile,” formerly known as JHP Pharmaceuticals, LLC), and Par Specialty Pharmaceuticals (“Par Specialty,” formerly known as Strativa Pharmaceuticals), which markets two branded products.

For 2014, Par Pharma had revenues of roughly $1.31 billion, with a compound annual revenue growth rate of 12.2%.

Par Pharma intends to use the net proceeds of this offering to repay indebtedness. It also intends to use the remainder of the net proceeds, if any, for working capital and other general corporate purposes, including supporting strategic growth opportunities in the future.

FULL FILING

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.